Astrazeneca Pharma India Ltd
Astrazeneca Pharma India Q1 FY26 earnings call: Revenue & Margins
Q1 FY26 earnings call: what management said on revenue, margins and capex.
Guidance rank: #20 of 83 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
What the Q1 FY26 call signalled
3 of 4 strong
The short version
AstraZeneca Pharma India expects robust future growth driven primarily by oncology and biopharmaceutical portfolios. The Company reported a 32% revenue growth in FY 2024-25 and a 25% growth in profit before exceptional items and tax, signaling strong momentum.
From Astrazeneca Pharma India Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- AstraZeneca Pharma India expects robust future growth driven primarily by oncology and biopharmaceutical portfolios.
- Company plans multiple new product launches over the coming years, including rare disease products like Soliris.
- The rare disease segment is an emerging focus area, aiming to build awareness and diagnosis capabilities in India, with potential to represent 15-16% of sales globally.
- Growth in oncology has been phenomenal, with cancer portfolio currently constituting around 70%-75% of sales; diversification efforts are ongoing to balance this.
- Revenue growth recorded was 32% in FY 2024-25; management is confident in sustaining high growth, with aspirations to double turnover every two years leading up to 2030.
- AstraZeneca India aims to become a billion-dollar company by 2030, contributing about 1% of the global portfolio.
2 more points from Astrazeneca Pharma India Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Astrazeneca Pharma India Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The Company continues to evaluate investments needed in India periodically.
- As a global company committed to India, AstraZeneca plans to make the right level of CAPEX investments over the next several years aligned with its plans for India.
- There is a focus on supporting growth through activities like marketing, medical personnel, and logistics, which impact costs.
- Investment in clinical trials, especially Phase IV trials for new product launches, is ongoing.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Astrazeneca Pharma India Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Astrazeneca Pharma India Ltd said on order book & pipeline — free account, 30 seconds.
Astrazeneca Pharma India Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹579 Cr, net profit ₹45 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Astrazeneca Phar's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- RPG LifeScience. (Q1 FY26)
168.9 crores vs Rs. Key concall takeaways from RPG Life Sciences Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
- SMS Pharma. (Q1 FY26)
Q1FY26 revenue from operations: ₹196.05 crore . Key concall takeaways from SMS Pharmaceuticals Ltd's Q1 FY26 earnings call — and how it ranks against sector…
- Morepen Laboratories Ltd (Q1 FY26)
Crores)**: . Key concall takeaways from Morepen Laboratories Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
- NGL Fine Chem Ltd (Q1 FY26)
Q1FY26 Revenue from operations: ₹104.19 crores . Key concall takeaways from NGL Fine Chem Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Astrazeneca Pharma India Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Astrazeneca Pharma India Ltd Q1 FY26 results?
AstraZeneca Pharma India expects robust future growth driven primarily by oncology and biopharmaceutical portfolios. The Company reported a 32% revenue growth in FY 2024-25 and a 25% growth in profit before exceptional items and tax, signaling strong momentum.
What is Astrazeneca Pharma India Ltd share price analysis?
Astrazeneca Pharma India Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 106.0 with a market cap of ₹20,271 Cr. Investors should review the full earnings analysis for detailed insights.
Is Astrazeneca Pharma India Ltd planning capital expenditure?
The Company continues to evaluate investments needed in India periodically.
Keep Astrazeneca Pharma India Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.